UPDATE: Morgan Stanley Starts Arcutis Biotherapeutics Inc. (ARQT) at Overweight

May 27, 2021 2:21 AM EDT
Get Alerts ARQT Hot Sheet
Price: $22.84 -1.89%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 22 | Down: 13 | New: 31
Trade Now! 
Join SI Premium – FREE
(Updated - May 27, 2021 4:24 AM EDT)

Morgan Stanley analyst David Lebowitz initiates coverage on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) with a Overweight rating and a price target of $52.00.

The analyst comments "Roflumilast has the efficacy and the safety to potentially become the rare topical dermatology blockbuster. Given that investors are typically skeptical about the prospects of topical therapeutics, we expect that ARQT shares would also benefit from a low bar. Initiate at OW and $52 PT."

For an analyst ratings summary and ratings history on Arcutis Biotherapeutics Inc. click here. For more ratings news on Arcutis Biotherapeutics Inc. click here.

Shares of Arcutis Biotherapeutics Inc. closed at $25.72 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Morgan Stanley